Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)

NANot yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

October 31, 2027

Conditions
Acute-on-Chronic Liver Failure (ACLF)
Interventions
OTHER

Standard medical therapy (SMT)

Standard medical therapy includes nutritional support (25-30 kcal/kg/day), lactulose, bowel wash, albumin, vasopressors (norepinephrine/terlipressin), antibiotics, antivirals for HBV reactivation, renal replacement therapy, and intensive care support as per institutional guidelines.

DEVICE

Double Plasma Molecular Adsorption System (DPMAS)

DPMAS therapy uses extracorporeal liver support with two sequential hemoadsorption cartridges (BS330 ion exchange resin and HA330-II neutral macroporous adsorption resin). Minimum 2 sessions (3-4 hours each) are performed within the first 7 days, with additional sessions if partial response is observed.

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT07178366 - Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) | Biotech Hunter | Biotech Hunter